Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast
Crossref DOI link: https://doi.org/10.1007/s11255-017-1671-2
Published Online: 2017-07-29
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ding, Honglin
Li, Ning
He, Xiaoning
Liu, Bing
Dong, Liming
Liu, Yili
Funding for this research was provided by:
LNCCC (LNCCC-D16-2015)
License valid from 2017-07-29